Teva Incoming CEO Yanai To Take The Helm In First Half 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva appoints CEO Makov’s successor, the leader of a generic crop protection chemicals firm, from outside pharma.
You may also be interested in...
Teva/Ivax Merger Gets FTC OK Pending Divestitures
Par and Barr will acquire 15 of the companies’ generic offerings.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4